Breast Cancer Research and Treatment

, Volume 98, Issue 1, pp 115–120 | Cite as

COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic fmolecular markers

  • F. Millanta
  • S. Citi
  • D. Della Santa
  • M. Porciani
  • A. Poli
Preclinical study

Summary

Cyclooxygenase (COX)-2 is an inducible enzyme linked to tumor growth and angiogenesis. Its expression occurs in a wide range of preneoplastic and neoplastic conditions in humans, including colon and breast carcinomas. We evaluated the role of COX-2 as a mediator of angiogenesis in feline and canine invasive carcinomas (IMCs) and its role as a prognostic indicator. COX-2 expression was assessed in neoplastic samples and healthy mammary glands by immunohistochemistry, and related to the following clinicopathological parameters: age, tumor size, histologic type, tumor grading, vessel invasion, estrogen (ER) and progesterone receptor (PR) status, Ki-67, HER-2 overexpression, microvessel density (MVD), VEGF expression and overall survival (OS). In both species, COX-2 immunoreactivity was not observed in healthy tissues, whereas 96% of feline and 100% of canine invasive carcinomas scored positive. In queens, COX-2 overexpression was significantly correlated to ER-negative status (p=0.04) and to increased PR (p=0.038) expression, and angiogenesis assessed by VEGF expression (p=0.002). In bitches an increased COX-2 expression was significantly correlated to HER-2 overexpression (p=0.013) and to tumor dedifferentiation (p=0.03). In both species increased levels of COX-2 were correlated to poorer prognosis (p=0.03 in dogs and p=0.002 in cats). COX-2 is expressed in mammary tissues during tumorigenesis and its expression is associated with a poorer prognosis in bitches and queens. The correlation of COX-2 expression and angiogenesis provides support for a potential role of COX-2 inhibitors for the prevention and the treatment of feline IMCs via their anti-angiogenic properties. In the canine species, moreover, COX-2 may be important for mediating HER-2 induced mammary tumors.

Keywords

angiogenesis cat COX-2 dog HER-2 mammary tumors prognosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Singh-ranger G, Mokbel K, The role of cyclooxygenase-2 (COX-2 in breast cancer, and implication of COX-2 inhibition Eur J Surg Oncol 28: 729–737, 2002PubMedCrossRefGoogle Scholar
  2. 2.
    Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T, Structure of the human cyclooxygenase-2 gene Biochem J 302: 723–727, 1994PubMedGoogle Scholar
  3. 3.
    Williams CS, Mann M, DuBois RN, The role of cyclooxygenases in inflammation, cancer, and development Oncogene 18: 7908–7916, 1999PubMedCrossRefGoogle Scholar
  4. 4.
    Thun MJ, Henley SJ, Parono C, Non-steroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues J Natl Cancer Inst 91: 1398–1403, 1999CrossRefGoogle Scholar
  5. 5.
    Khan KNM, Knapp DW, De Nicola DB, Harris RK Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs Am J Vet Res 61: 478–481, 2000PubMedCrossRefGoogle Scholar
  6. 6.
    Khan KNM, Stanfield KM, Trajkovic D, Knapp DW, Expression of cyclooxygenase-2 in canine renal cell carcinoma Vet Pathol 38: 116–119, 2001PubMedCrossRefGoogle Scholar
  7. 7.
    McEntee MF, Cates JM, Neilsen N, Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs Vet Pathol 39: 428–436, 2002PubMedCrossRefGoogle Scholar
  8. 8.
    Beam SL, Rassnick KM, Moore AS, McDonough SP, An immunohistochemical study of Cyclooxygenase-2 expression in various feline neoplasms Vet Pathol 40: 496–500, 2003PubMedCrossRefGoogle Scholar
  9. 9.
    Mohammed SI, Khan KNM, Sellers RS, Hayek MG, De Nicola DB, Wu L, Bonney PL, Knapp DW, Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer Prostag Leukotr Ess 70: 479–483, 2004CrossRefGoogle Scholar
  10. 10.
    Mann M, Sheng H, Shao J, William CS, Pisacane PI, Sliwkowski MX, DuBois RN, Targeting cyclooxygenase-2 and HER-2/neu pathways inhibits colorectal carcinoma growth Gastronterology 120: 1713–1719, 2001CrossRefGoogle Scholar
  11. 11.
    Kirkpatrick K, Ogunkolade W, Elkak A, et al., The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer Curr Med Res Opin 18: 237–241, 2002PubMedCrossRefGoogle Scholar
  12. 12.
    Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M, Dubois RN, Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 18:237–241, 1998Google Scholar
  13. 13.
    Millanta F, Lazzeri G, Vannozzi I, Viacava P, Poli A, Correlation of Vascular Endothelial Growth Factor Expression to overall survival in feline invasive mammary carcinomas Vet Pathol 39(6): 690–696, 2002bCrossRefGoogle Scholar
  14. 14.
    Restucci B, Papparella S, Maiolino P, De Vico G, Expression of Vascular Endothelial Growth Factor in canine mammary tumours Vet Pathol 39: 488–493, 2002PubMedCrossRefGoogle Scholar
  15. 15.
    Mehta RG, Moon RC, Characterization of effective chemopreventive agents in mammary gland in vitso using an initiation-promotion protocol Anticancer Res 11: 593–596, 1991PubMedGoogle Scholar
  16. 16.
    Chang SH, Liu CH, Conway R, Han DK, Nithipatilom K, Trifan OC, Lane TF, Hla T, Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression Proc Natl Acad Sci 101(2): 591–596, 2004PubMedCrossRefGoogle Scholar
  17. 17.
    Misdorp W, Else RW, Hellmen E, Lipscomb TP: Histological Classification of Mammary Tumours of the Dog and the Cat. Second series. Vol. VII. WHO International Histological Classification of Tumors of Domestic Animals. Armed Forces Institute of Pathology, American Registry of Pathology, Washington DC, pp. 16–27, 1999Google Scholar
  18. 18.
    Elston CW, Ellis IO, Pathological prognostic factors in breast cancer. I. Value of histological grade breast cancer: experience from a large study with a long-term follow-up Histopathology 19: 403–410, 1991PubMedCrossRefGoogle Scholar
  19. 19.
    Millanta F, Lazzeri G, Mazzei M, Vannozzi I, Poli A, MIB-1 labelling index in feline dysplastic and neoplastic mammary lesions and its relationship with post-surgical prognosis Vet Pathol 39(1): 120–126, 2002aCrossRefGoogle Scholar
  20. 20.
    Millanta F, Calandrella M, Citi S, Della Santa D, Poli A, Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential Vet Pathol 42:30–34, 2005aCrossRefGoogle Scholar
  21. 21.
    Millanta F, Calandrella M, Bari G, Niccolini M, Vannozzi I, Poli A, Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues Res Vet Sci 79: 225–232, 2005bCrossRefGoogle Scholar
  22. 22.
    Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC, Cyclo-oxygenase2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer J Clin Pathol 55: 429–4343, 2002PubMedGoogle Scholar
  23. 23.
    Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J, Prognostic significance of elevated Cyclooxygenase-2 expression in breast cancer Cancer Res 62: 632–635, 2002PubMedGoogle Scholar
  24. 24.
    Davies G, Salter J, Hils M, Martin LA, Sacks N, Dowsett M, Correlation between Cyclooxygenase-2 expression and angiogenesis in human breast cancer Clin Cancer Res 9: 2651–2656, 2003PubMedGoogle Scholar
  25. 25.
    Dore M, Lanthier I, Sirois J, Cycloxygenase-2 expression in canine mammary tumors Vet Pathol 40: 207–212, 2003PubMedCrossRefGoogle Scholar
  26. 26.
    Heller DA, Clifford CA, Goldschmidt DE, Holt FS, Shofer FS, Smith A, Sorenmo KU, Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma Vet Pathol 42: 776–780, 2005PubMedCrossRefGoogle Scholar
  27. 27.
    Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R Regulation of cyclooxygenase-2 pathway by HER2 receptor Oncogene 18:305–314, 1999PubMedCrossRefGoogle Scholar
  28. 28.
    Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C, COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features Histopathology 46: 561–568, 2005PubMedCrossRefGoogle Scholar
  29. 29.
    Gately S, Li WW, Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy Sem Oncol 31(suppl.7): 2–11, 2004CrossRefGoogle Scholar
  30. 30.
    Fosslien E, Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis Ann Clin Lab Sci 31: 325–348, 2001PubMedGoogle Scholar
  31. 31.
    Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM, Cyclooxygenase in cancer:progress and perspective Cancer Lett 215: 1–20, 2004PubMedCrossRefGoogle Scholar
  32. 32.
    Harris RE, Kasbari S, Farrar WB, Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer Oncol Rep 6: 71–73, 1999PubMedGoogle Scholar
  33. 33.
    Harris RE, Alshafie GA, Abou-Issa H, Seibert K, Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor Cancer Res 60: 2101–2103, 2000PubMedGoogle Scholar
  34. 34.
    Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K, Antiangiogenic and antitumor activities of cyclooxigenase-2 inhibitors Cancer Res 60: 1306–1311, 2000PubMedGoogle Scholar
  35. 35.
    Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ, Cyclooxygenase-2: a target for the prevention and treatment of breast cancer Endocr Relat Cancer 8:97–114, 2001PubMedCrossRefGoogle Scholar
  36. 36.
    Mohammed SI, Bennett PF, Craig BA, et al., Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response,apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer Cancer Res 62: 356–358, 2002PubMedGoogle Scholar
  37. 37.
    Schmidt BR, Glickman NW, De Nicola DB, de Gortari AE, Knapp DW Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs J Am Vet Med Assoc 218: 1783–1786, 2001PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • F. Millanta
    • 1
  • S. Citi
    • 2
  • D. Della Santa
    • 2
  • M. Porciani
    • 1
  • A. Poli
    • 1
    • 3
  1. 1.Department of Animal Pathology, School of Veterinary MedicineUniversity of PisaPisaItaly
  2. 2.Clinic Department, School of Veterinary MedicineUniversity of PisaPisaItaly
  3. 3.Department of Animal Pathology, School of Veterinary MedicineUniversity of PisaPisaItaly

Personalised recommendations